EUVIMEDEUVIMED entdecken
Open Access

Tumor-informed circulating tumor DNA assay for surveillance post-liver transplantation in patients with hepatocellular and cholangiocarcinoma

Maen Abdelrahim iD, Ashton A Connor iD, Abdullah Esmail iD, Ahmed Elaileh iD, Souha Farhat iD, Sudha Kodali iD, David W Victor iD, Elizabeth W Brombosz iD, Ashish Saharia iD, Linda W Moore iD, R Mark Ghobrial iD

Journal of Gastrointestinal Oncology · 2025-08 · 16 (4) · 1573-1585

DOI: 10.21037/jgo-24-791 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gastrointestinal Oncology, 2025-08. Verfasst von Maen Abdelrahim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Liver transplantation (LT) for primary liver cancers achieves excellent patient outcomes, but a minority recur with poor prognosis. Survival may be improved by earlier recurrence detection. This study aims to evaluate the feasibility and performance of a personalized tumor-informed assay utilizing circulating tumor DNA (ctDNA) from peripheral blood for surveillance after LT in patients with hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA).

Methods

Here, we test whether a personalized tumor-informed assay utilizing ctDNA from peripheral blood informs post-LT surveillance. Personalized ctDNA assays were employed for surveillance in 38 LT recipients, alongside standard-of-care imaging and peripheral tumor biomarkers [alpha-fetoprotein (AFP), carbohydrate antigen 19-9 (CA19-9)].

Results

Recurrence was detected radiologically in 6 patients, with positive ctDNA assays in 3 and negative/insufficient to process (ITP) in 3. Nine ITP ctDNA assays were due to insufficient primary tumor tissue. In 31 patients without ITP ctDNA tests, the sensitivity and specificity of ctDNA were 75% [95% confidence interval (CI): 19-99%] and 100% (95% CI: 87-100%). Standard-of-care tumor biomarkers had sensitivity and specificity of 75% (95% CI: 19-99%) and 93% (95% CI: 76-99%), respectively (P>0.99 and P=0.16; McNemar χ2). Only 1 patient had ctDNA positive prior to imaging-based diagnosis.

Conclusions

This study corroborates the feasibility of ctDNA assays for recurrence surveillance in LT recipients. The results imply that ctDNA assays show promise in confirming recurrence and minimizing the need for invasive biopsy. However, additional prospective studies are needed to confirm ctDNA test utility in surveillance protocols.

Schlagwörter

Stichwörter der Autor:innen

Transplant oncologycholangiocarcinoma (CCA)circulating tumor DNA (ctDNA)hepatocellular carcinoma (HCC)liquid biopsyliver transplantation (LT)

Autor:innen und Institutionen

  • Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
  • Cockrell Center of Advanced Therapeutics Phase I Program, Houston Methodist Research Institute, Houston, TX, USA.
  • Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
  • Sherrie and Alan Conover Center for Liver Disease and Transplantation, JC Walter Jr. Center for Transplantation, Houston Methodist Hospital, Houston, TX, USA.
  • Department of Surgery, Houston Methodist Hospital, Houston, TX, USA.
  • Department of Surgery, Weill Cornell Medical College, New York, NY, USA.

ORCID-Profile: Maen Abdelrahim, Ashton A Connor, Abdullah Esmail, Ahmed Elaileh, Souha Farhat, Sudha Kodali, David W Victor, Elizabeth W Brombosz, Ashish Saharia, Linda W Moore, R Mark Ghobrial

Zitieren

APA

Abdelrahim, M., Connor, A. A., Esmail, A., Elaileh, A., Farhat, S., Kodali, S., Victor, D. W., Brombosz, E. W., Saharia, A., Moore, L. W., & Ghobrial, R. M. (2025). Tumor-informed circulating tumor DNA assay for surveillance post-liver transplantation in patients with hepatocellular and cholangiocarcinoma. Journal of Gastrointestinal Oncology, 16(4), 1573-1585. https://doi.org/10.21037/jgo-24-791

Vancouver

Abdelrahim M, Connor AA, Esmail A, Elaileh A, Farhat S, Kodali S, et al. Tumor-informed circulating tumor DNA assay for surveillance post-liver transplantation in patients with hepatocellular and cholangiocarcinoma. Journal of Gastrointestinal Oncology. 2025;16(4):1573-1585. doi:10.21037/jgo-24-791

BibTeX
@article{Abdelrahim2025,
  author = {Abdelrahim, Maen and Connor, Ashton A and Esmail, Abdullah and Elaileh, Ahmed and Farhat, Souha and Kodali, Sudha and Victor, David W and Brombosz, Elizabeth W and Saharia, Ashish and Moore, Linda W and Ghobrial, R Mark},
  title = {Tumor-informed circulating tumor DNA assay for surveillance post-liver transplantation in patients with hepatocellular and cholangiocarcinoma},
  journal = {Journal of Gastrointestinal Oncology},
  year = {2025},
  volume = {16},
  number = {4},
  pages = {1573--1585},
  doi = {10.21037/jgo-24-791}
}
Kostenlos starten →